AI poses 'extinction' risk comparable to nuclear war, CEOs of OpenAI, DeepMind, and Anthropic say
The general public is also wary of the tech world's new obsession. A recent poll of more than 4,000 US adultsAI fears have been partially spurred on by an arms race between Big Tech companies.
Google, Meta, and Microsoft have been pouring investment into AI development and have rushed to launchGovernments around the world have taken note of the acceleration and are looking to try and regulate the tech. In Europe, lawmakers are pushing aheadSign up for notifications from Insider! Stay up to date with what you want to know.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
OpenAI CEO Altman backtracks after threatening to exit Europe over overregulation concernsSam Altman, CEO of ChatGPT maker OpenAI, backtracked on a warning that the company may have to stop operating in Europe if the EU over-regulates AI, saying the company has no plans to leave.
Read more »
Meet Sam Altman: OpenAI CEO, prepper, Silicon Valley royaltyThe man behind ChatGPT is also serious about survival prepping, once telling The New Yorker: 'I have guns, gold, potassium iodide, antibiotics, batteries, water, gas masks from the Israeli Defense Force, and a big patch of land in Big Sur I can fly to.'
Read more »
OpenAI isn’t doing enough to make ChatGPT’s limitations clearChatGPT needs more prominent warning labels.
Read more »
OpenAI CEO Signs Letter Warning AI Could Cause Human 'Extinction'Sam Altman, the CEO of OpenAI, has signed onto a one-sentence open letter warning about the 'extinction' dangers posed by AI, LOL.
Read more »
AI Could Cause Human ‘Extinction,’ Tech Leaders WarnOpenAI chief Sam Altman and Google DeepMind CEO Demis Hassabis were among the tech leaders warning AI could be as dangerous as pandemics and nuclear weapons.
Read more »
CEOs see ChatGPT, generative AI as 'Ozempic' style cure-allCEOs see ChatGPT as an 'Ozempic' miracle drug that can cut costs and boost efficiency. Right now, they're wrong.
Read more »